Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: CD4 Antigens; CD4 Immunoadhesin; Hybrid CD4; Recombinant CD4 Immunoglobulin G; Recombinant human CD4 Immunoglobulin G; Recombinant soluble CD4 Immunoglobulin G; rsCD4 IgG

Latest Information Update: 12 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antivirals; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV infections; Idiopathic thrombocytopenic purpura

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 28 Oct 2005 Discontinued - Phase-I for HIV-associated Idiopathic thrombocytopenic purpura in USA (IV)
  • 28 Oct 2005 Discontinued-I for HIV infections in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top